Search research articles
Contact Us
Filters
Showing results (41-50 of 110) with videos related to
Page
of 11
Sort By:
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
February 7, 2020
[Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma]
Jendrik Becker-Assmann, Mohammad H Fard-Aghaie, Alexandros Kantas, et al.
Zeitschrift Fur Gastroenterologie
|
December 5, 2014
[Current recommendations for the treatment of chronic hepatitis C]
Christoph Sarrazin, Thomas Berg, Peter Buggisch, et al.
Journal of Hepatology
|
November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
David Burger, David Back, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)
|
August 31, 2006
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn, Marc Lutgehetmann, Maura Dandri, et al.
Hepatology (Baltimore, Md.)
|
October 11, 2008
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, et al.
Journal of Viral Hepatitis
|
February 11, 2019
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
Peter Ferenci, Stefan Bourgeois, Peter Buggisch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 25, 2011
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection
Johannes Wiegand, Konrad Neumann, Stephan Böhm, et al.
Zeitschrift Fur Gastroenterologie
|
December 17, 2014
[In Process Citation]
Christoph Sarrazin, Thomas Berg, Peter Buggisch, et al.
Plos One
|
May 10, 2021
Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
Peter Buggisch, Hans Heiken, Stefan Mauss, et al.
The American Journal of Gastroenterology
|
October 16, 2008
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
Elke M Hennes, Ye H Oo, Christoph Schramm, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 110) with videos related to
Sort By:
Page
of 11
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
February 7, 2020
[Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma]
Jendrik Becker-Assmann, Mohammad H Fard-Aghaie, Alexandros Kantas, et al.
Zeitschrift Fur Gastroenterologie
|
December 5, 2014
[Current recommendations for the treatment of chronic hepatitis C]
Christoph Sarrazin, Thomas Berg, Peter Buggisch, et al.
Journal of Hepatology
|
November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
David Burger, David Back, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)
|
August 31, 2006
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn, Marc Lutgehetmann, Maura Dandri, et al.
Hepatology (Baltimore, Md.)
|
October 11, 2008
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, et al.
Journal of Viral Hepatitis
|
February 11, 2019
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
Peter Ferenci, Stefan Bourgeois, Peter Buggisch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 25, 2011
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection
Johannes Wiegand, Konrad Neumann, Stephan Böhm, et al.
Zeitschrift Fur Gastroenterologie
|
December 17, 2014
[In Process Citation]
Christoph Sarrazin, Thomas Berg, Peter Buggisch, et al.
Plos One
|
May 10, 2021
Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
Peter Buggisch, Hans Heiken, Stefan Mauss, et al.
The American Journal of Gastroenterology
|
October 16, 2008
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
Elke M Hennes, Ye H Oo, Christoph Schramm, et al.
Page
of 11